AstraZeneca to Invest USD2.5 Billion in New R&D Center in Beijing
Since 2023, AstraZeneca has invested more than USD1.7 billion to expand its production in China, including spending USD750 million to build a new inhaler production base in Qingdao, eastern Shandong province, and USD475 million for a small molecule drug factory in Wuxi, eastern Jiangsu province.
AstraZeneca announced an investment of $2.5 billion in Beijing to establish its sixth global strategic R&D centre together with major research and manufacturing agreements that will further advance ...
AstraZeneca's five-year US$2.5 billion investment, announced on Friday, includes a new research-and-development center in Beijing and a research agreement with Harbour BioMed. The U.K. firm will also ...
Tallying up a wide range of investments, AstraZeneca said it is pumping $2.5 billion into Beijing. The figure includes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback